Abera Bioscience (ABERA) Q1 2026 earnings summary

Executive summary

• High organizational activity with parallel progress in pneumococcal vaccine clinical preparations and accelerated preclinical influenza work, strengthening both short-term milestones and long-term potential in next-generation vaccines.

• GMP production for the pneumococcal vaccine is in its final stage, with regulatory and clinical study preparations ongoing in collaboration with Radboud UMC.

• Preclinical influenza studies show promising results, with strong immune responses and effective viral elimination in animal models.

• A directed share issue raised approximately 10 MSEK, enabling increased R&D pace and parallel development steps.

Financial highlights

• Net sales for Q1 2026 were 0 KSEK, with other operating income of 3,553 KSEK, mainly from grants.

• Operating expenses increased to -9,386 KSEK (from -3,575 KSEK YoY), driven by one-time GMP production costs and expanded preclinical studies.

• Net result for the quarter was -5,796 KSEK (12 KSEK YoY), reflecting higher R&D and personnel costs.

• Cash and bank balances at March 31, 2026, were 26,041 KSEK (5,501 KSEK YoY), supported by the recent share issue.

• Equity increased to 23,485 KSEK (8,667 KSEK YoY), with a solidity of 76%.

Outlook and guidance

• Clinical trial application for the pneumococcal vaccine is imminent, with first-in-human studies planned for 2026.

• Continued focus on advancing both pneumococcal and influenza vaccine programs toward clinical phases.

• Ongoing support from CEPI and UK Vaccine Network ensures funding for pandemic preparedness and vaccine platform development through at least mid-2026.